Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed Plus Osimertinib for EGFR-mutated NSCLC with Leptomeningeal Metastasis
NCT06304441Recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pemetrexed in leptomeningeal metastasis (LM) (2 arms), sponsored by Guangzhou Medical University. Primary endpoint: Clinical Response Rate at 6 months. Started Apr 2024; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06304441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304441.